Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 18/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963983 | 1.00 | CCR5 (0.50) | CCR5 | |
| SCHEMBL13886981 | 0.87 | MEN1 (0.50) | CCR5 | |
| SCHEMBL5760000 | 0.83 | CCR5 (0.68) | CCR5 | |
| SCHEMBL5760398 | 0.83 | CCR5 (0.68) | CCR5 | |
| SCHEMBL13894807 | 0.79 | MEN1 (0.41) | CCR5 | |
| SCHEMBL16202069 | 0.72 | CCR5 (0.41) | CCR5 | |
| SCHEMBL24130848 | 0.70 | SLC6A2 (0.40) | CCR5 | |
| Hydrochloric Acid SCHEMBL1448673 | 0.69 | LTA4H (0.52) | CCR5 | |
| SCHEMBL1135130 | 0.67 | MEN1 (0.67) | — | |
| Bromide SCHEMBL10966041 | 0.66 | MEN1 (0.65) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009173688-A | SYNTHESIS OF (4-BROMOPHENYL)(4-PIPERIDYL)METHANONE-(Z)-O-ETHYLOXIME AND SALTS | SCHERING CORP | 2009-08-06 | — | — | JP | disclosed |
| US-7524963-B2 | Synthesis of (4-bromophenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524963-B2 | Synthesis of (4-bromophenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050171159-A1 | Antiinflammatory agents; rheumatic diseases | WONG GEORGE S (US) | 2005-08-04 | — | — | US | disclosed |
| US-6914142-B2 | Synthesis of (4-bromopnenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts | SCHERING CORPORATION (US) | 2005-07-05 | — | — | US | disclosed |
| US-20030092731-A1 | Synthesis of (4-bromopnenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092731-A1 | Synthesis of (4-bromopnenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts | PAM, PNMT, MSMO1 | CCR5 868/4885 |
| US-20050171159-A1 | Antiinflammatory agents; rheumatic diseases | PTGES3, PTGES, PTGES2 | CCR5 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.